Reduction of norepinephrine versus vasopressin in the stabilization phase of septic shock: RENOVA clinical trial

What Was Tested

Researchers studied Vasopressin in this randomized controlled trial publication.

Evaluate the incidence of hypotension during the weaning phase of vasopressors.

Who Took Part

The abstract describes 91 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

91 adult patients over 18 years of age with septic shock (according to Sepsis-3).

How the Study Was Run

The researchers set it up as a randomized and open-label study.

The patients were allocated by chance, so the Vasopressin group and the comparison group should start out alike.

Everyone knew when Vasopressin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

A time span of 18 years appears in the methods.

A single-center, open-label randomized clinical trial between May and December 2022.

A tertiary care academic medical center.

Additionally, the clinical impact of this hypotension was assessed through mortality, length of hospital stay, duration of vasopressor use, incidence of arrhythmias, and prevalence of hemodialysis.

What Was Measured

The subject headings attached to it are Hypotension, Incidence, Length of Stay, Norepinephrine, Renal Dialysis, Shock, Septic and Vasoconstrictor Agents.

The authors tagged it with the keywords Hipotensión, Noradrenalina, Sepsis, Septicemia, Vasoconstrictores and Vasoconstrictors.

What This Means in Plain Language

The paper is a randomized and open-label study of Vasopressin in 91 patients over 18 years.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Medicina intensiva), a journal based in Spain.

More context: the Vasopressin compound page, all human trials.